Characterising a complex MRI contrast agent
WP2 selected the commercially available preclinical MRI contrast agent FeraSpin™ R as a case-study material. The formulation contains carboxy-dextran-coated iron oxide nanoparticles and presents a broad particle-size distribution, including small cores and larger particle assemblies. Because some agglomeration may be induced by sample preparation, the study carefully distinguishes what each technique and sampling scale can establish.
Partners combined SAXS, MD AF4, microscopy, thermal analysis and spectroscopic techniques to investigate particle size, subpopulations, chemical homogeneity and surface coating properties. The comparison showed the value and the limitations of combining results obtained at different length scales and sampling volumes.





